Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...
Zacks Investment Research on MSN

Why Vertex Pharmaceuticals (VRTX) is a top momentum stock for the long term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

US close: Stocks pull back ahead of Fed decision

Wall Street stocks declined on Monday despite some M&A excitement in the entertainment sector, as markets pulled back from ...
Precision Medicine Online

Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...